Investigating Metabolic, Brain, and Cognitive Alterations Through Bariatric Surgery
NCT07704229, Not yet recruiting, Laval University
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Investigating Metabolic, Brain, and Cognitive Alterations Through Bariatric Surgery | ClinicalTrials.gov |
| NCT number | NCT07704229 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 150 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Laval University | ClinicalTrials.gov |
| Conditions | Obesity, Morbid | ClinicalTrials.gov |
| Interventions | Sleeve Gastrectomy | ClinicalTrials.gov |
| First posted | 2026-07-15 | ClinicalTrials.gov |
| Last updated | 2026-07-16 | ClinicalTrials.gov |
Registered outcomes 37
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Estimated Brain Age | Baseline to 36 months | Difference between MRI-predicted brain age and chronological age based (delta age, years) derived from a validated machine learning model based on MRI modalities. | ClinicalTrials.gov |
| Secondary | Change in Executive Function Composite Score | Baseline to 36 months | Composite z-score derived from the Stroop Color-Word Interference test, Trail Making Test Part B and Digit Span Test ( z-score change). | ClinicalTrials.gov |
| Secondary | Change in Processing Speed Composite Score | Baseline to 36 months | Composite z-score derived from the Digit Symbol Substitution Test, Trail Making Test Part A, Stroop Color-Word Interference (z-score change). | ClinicalTrials.gov |
| Secondary | Change in Memory Composite Score | Baseline to 36 months | Composite z-score derived from the Rey Auditory Verbal Learning Test (z-score change). | ClinicalTrials.gov |
| Secondary | Change in Global Cognition | Baseline to 36 months | Montreal Cognitive Assessment (MoCA) score (0-30), with higher scores indicating better cognitive performance. | ClinicalTrials.gov |
| Secondary | Change in White Matter Fractional Anisotropy (FA) | Baseline to 36 months | Mean fractional anisotropy (FA) derived from diffusion tensor imaging (dimensionless, 0-1); Higher FA values generally reflect greater white matter microstructural organization and fiber tract integrity. | ClinicalTrials.gov |
| Secondary | Change in White Matter Mean Diffusivity (MD) | Baseline to 36 months | Mean diffusivity (MD; mm²/s) derived from diffusion tensor imaging. Higher MD values generally reflect reduced white matter microstructural integrity and increased water diffusion within tissue. | ClinicalTrials.gov |
| Secondary | Change in Grey Matter Density | Baseline to 36 months | Grey matter density measured using voxel-based morphometry derived from T1-weighted structural MRI (arbitrary units). | ClinicalTrials.gov |
| Secondary | Change in Grey Matter Cortical Thickness and Surface Area | Baseline to 36 months | Mean cortical thickness (mm) and total surface area (mm²) derived from T1-weighted MRI. | ClinicalTrials.gov |
| Secondary | Change in White Matter Hyperintensity Volume | Baseline to 36 months | Total white matter hyperintensity volume (mm3) segmented from 3D FLAIR MRI. | ClinicalTrials.gov |
| Secondary | Change in Cerebral Artery Diameter | Baseline to 36 months | Mean arterial lumen diameter (mm) measured in predefined cerebral arteries using TOF-MRA. | ClinicalTrials.gov |
| Secondary | Change in Cerebral Artery Volume | Baseline to 36 months | Total cerebral arterial volume (mm³) measured from TOF-MRA using automated vessel segmentation. | ClinicalTrials.gov |
| Secondary | Change in Cerebral Blood Flow | Baseline to 36 months | Regional and whole-brain cerebral blood flow (mL/100g/min) derived from ASL sequences. | ClinicalTrials.gov |
| Secondary | Change in Brain Iron Content as Measured by QMRI Multi-Parameter Mapping Protocol | Baseline to 36 months | Magnetic susceptibility derived from quantitative susceptibility mapping (QSM), a surrogate marker of cerebral iron content (seconds). | ClinicalTrials.gov |
| Secondary | Change in Brain Water Content as Measured by QMRI Multi-Parameter Mapping Protocol | Baseline to 36 months | Quantitative MRI estimate of brain Water content (%). | ClinicalTrials.gov |
| Secondary | Change in Brain Myelin Integrity as Measured by QMRI Multi-Parameter Mapping Protocol | Baseline to 36 months | Myelin quantitative MRI measure (myelin water fraction, %). | ClinicalTrials.gov |
| Secondary | Change in Body Mass Index | Baseline to 36 months | BMI (kg/m2) | ClinicalTrials.gov |
| Secondary | Change in Percent Excess Weight Loss | Baseline to 36 months | Excess weight loss (%) | ClinicalTrials.gov |
| Secondary | Change in Body Composition | Baseline to 36 months | Total weight (kg), Fat mass (kg) measured by bioimpedance or DXA. | ClinicalTrials.gov |
| Secondary | Change in Adiposity | Baseline to 36 months | Waist, Hip and Neck circumference (cm). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)